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ABSTRACT
Background Familial Hypercholesterolaemia (FH) is an
autosomal dominant disease, caused by mutations in
LDLR, APOB or PCSK9, which results in high levels of
LDL-cholesterol (LDL-C) leading to early coronary heart
disease. An autosomal recessive form of FH is also
known, due to homozygous mutations in LDLRAP1. This
study assessed the utility of an exome capture method
and deep sequencing in FH diagnosis.
Methods Exomes of 48 deﬁnite FH patients, with no
mutation detected by current methods, were captured by
Agilent Human All Exon 50Mb assay and sequenced on
the Illumina HiSeq 2000 platform. Variants were called by
GATK and SAMtools.
Results The mean coverage of FH genes varied
considerably (PCSK9=23x, LDLRAP1=36x, LDLR=56x
and APOB=93x). Exome sequencing detected 17 LDLR
mutations, including three copy number variants, two
APOB mutations, missed by the standard techniques,
two LDLR novel variants likely to be FH-causing, and ﬁve
APOB variants of uncertain effect. Two variants called in
PCSK9 were not conﬁrmed by Sanger sequencing. One
heterozygous mutation was found in LDLRAP1.
Conclusions High-throughput DNA sequencing
demonstrated its efﬁciency in well-covered DNA regions,
in particular LDLR. This highly automated technology is
proving to be effective for heterogeneous diseases and
may soon replace laborious conventional methods.
However, the poor coverage of gene promoters and
repetitive, or GC-rich sequences, remains problematic,
and validation of all identiﬁed variants is currently
required.
INTRODUCTION
Familial Hypercholesterolaemia (FH) is a common
autosomal dominant genetic disease caused by
mutations affecting the plasma clearance of
LDL-cholesterol (LDL-C).1 FH patients have ele-
vated levels of total and low-density lipoprotein
(LDL) from birth, and if untreated, develop coron-
ary heart disease (CHD) by the age of 55 in 50% of
men and 30% of women.2 In addition to the
increased LDL-C, a proportion of FH patients is
characterised by the occurrence of tendon xantho-
mas (TX), and the UK Simon Broome criteria3 clas-
siﬁes TX-positive patients as Deﬁnite FH (DFH),
and TX-negative patients as Possible FH (PFH),
with the DFH group having a three times higher
risk of developing CHD when compared with the
PFH subjects.4 5 Statin therapy has been proven
highly effective in the treatment of FH patients,
and the importance of an early identiﬁcation of FH
patients for the statin treatment has been demon-
strated6 and recently highlighted.7
The clinical phenotype of FH is known to be
due to mutations in three genes encoding proteins
involved in the clearance of LDL-C from the
plasma, LDLR, APOB and PCSK9. There are over
1200 different LDLR mutations,8 but only one
common APOB (c.10580G>A, p.R3527Q) and one
PCSK9 (c.1120G>T, p.D374Y) mutation, reported
in the UK population.9 The majority of pathogenic
LDLR variants are single nucleotide changes
leading to signiﬁcant alterations in the amino acid
sequence of the mature protein, or creation of a
truncated peptide. FH is also caused by variants
that affect correct splicing, and by changes in the
transcription-factor-binding elements located in
the promoter.10
While LDLR/APOB/PCSK9 mutations cause a
dominant pattern of inheritance, an autosomal
recessive hypercholesterolaemia (ARH) has also
been observed. The locus for ARH was mapped to a
chromosome 1 gene, the LDLRAP1, in which both
homozygous and compound heterozygous muta-
tions can be found.11 Most of the ARH-causing
mutations are due to premature stop codons.
In 2008, the UK National Institute for Health
and Clinical Excellence (NICE) guidelines were
published, and included a recommendation that all
FH patients be offered a DNA test to conﬁrm their
diagnosis and, so that mutation conﬁrmation
could be used, to cascade-test their ﬁrst-degree rela-
tives. Newly identiﬁed patients can then be offered
statin treatment.12 In most laboratories, FH muta-
tion screening includes use of commercially avail-
able kits designed to test for the most common
mutations, such as Elucigene FH20 (Gen-Probe Life
Sciences, UK) and LIPOchip (Progenica Biopharma,
Spain), and for large gene rearrangements (dele-
tions or duplications), which account for 4%–5%
of all FH mutations.13 However, in the UK, due to
the highly heterogeneous nature of the population
this approach is not fully effective, and many
patient samples require screening the LDLR pro-
moter and coding regions, splice sites and splice
branch points for causative mutations, and in the
diagnostic laboratory this is currently performed
using Sanger sequencing. Because of the time and
labour of these methods, there has been interest in
next-generation sequencing (NGS) technology for
the diagnosis of genetic disorders. However,
whether NGS is ready for clinical use has been
questioned.14 Main limitations of the technology
include the requirement for complex data analysis,
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signiﬁcant computing infrastructure with respect to data ana-
lysis and storage, and legal and ethical issues associated with
incidental ﬁndings from acquiring whole exome data. In the
research laboratory a four-phased approach is used to screen FH
patients to identify the causative mutation, using the commer-
cially available Ampliﬁcation Refractory Mutation System kit,
which tests for 20 of the most common UK mutations, fol-
lowed by High-Resolution Melting (HRM) to detect changes
within the coding region and splice sites of FH genes, followed
by Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA),
for the detection of large LDLR gene rearrangements, and
ﬁnally Sanger sequencing.15–17 Using standard molecular diag-
nostic techniques, an FH-causing mutation can be detected in
20%–30% of PFH patients, and in 60%–80% of DFH patients.18
The UK10K is a large-scale deep-sequencing project, based on
collaboration between multiple investigators at the Wellcome
Trust Sanger Institute, and clinical experts in different genetic
diseases. A total of 125 FH samples with no LDLR/APOB/
PCSK9 mutation are currently in the exome sequencing pipe-
line, as a part of the Rare Diseases group of the UK10K. The
aim of the project is to provide collaborators with high-quality
exome data, which will be used for the discovery of novel
disease genes. This paper reports the sequencing results of the
ﬁrst 48 FH exomes, and discusses sensitivity problems of the
current FH mutation-screening methods, as well as demonstrat-
ing advantages and limitations of the whole exome sequencing
approach.
MATERIALS AND METHODS
Patients’ selection
Forty-eight unrelated FH patients were selected from the
Simon Broome FH register.19 All individuals were Caucasian
and attended a lipid clinic in London, Oxford or Manchester.
Patients were diagnosed using the UK Simon Broome criteria as
DFH on the basis of the presence or history of TX. The entire
promoter and coding regions, including splice sites, of the
LDLR gene were screened by the HRM method, as previously
described,16 on the Rotor-Gene (6000) real-time rotary analyser.
Patients were screened for presence of the APOB mutation, p.
(R3527Q), using a restriction enzyme digest,20 and the entire
coding region of the PCSK9 was examined by HRM.17
Fragments with a heterozygous melting curve were analysed
further by direct sequencing. Screening for large rearrangements
within the LDLR gene was done using the MLPA21 SALSA
P062 LDLR kit from MRC-Holland (Amsterdam). One hundred
and ninety ﬁve non-FH Caucasian samples, sequenced in paral-
lel with the FH cohort, as a part of the UK10K rare disease arm
project (http://www.uk10k.org/studies/rarediseases.html), were
used as controls. None of these subjects had disorders known
to affect plasma lipid levels.
Whole exome sequencing
Genomic DNA (1–3 μg), extracted from blood,22 was sheared to
100–400 bp using a Covaris E210 or LE220 (Covaris, Woburn,
Massachusetts, USA). Sheared DNA was subjected to Illumina
paired-end DNA library preparation and enriched for target
sequences (Agilent Technologies, Santa Clara, CA, USA;
Human All Exon 50 Mb - ELID S02972011) according to the
manufacturer ’s recommendations (Agilent Technologies, Santa
Clara, CA, USA; SureSelectXT Automated Target Enrichment
for Illumina Paired-End Multiplexed Sequencing). Enriched
libraries were sequenced (eight samples over two lines) using
the HiSeq 2000 platform (Illumina) as paired-end 75 base reads
according to the manufacturer ’s protocol.
Bioinformatic analysis
To improve raw alignment BAMs for single nucleotide poly-
morphism (SNP) calling, we realigned around known (1000
Genomes pilot) indels, and recalibrated base quality scores using
GATK. BAQ tags were added using samtools calmd. BAMs were
merged to sample level and duplicates marked using Picard.
Variants (SNPs and indels) were called on each sample individu-
ally with both samtools mpileup (0.1.17) and GATK
UnifedGenotyper (1.3–21), restricted to exon bait regions plus or
minus a 100 bp window. Various quality ﬁlters were applied to
each of the callsets separately. Calls were then merged, giving
preference to GATK information when possible. Calls were
annotated with 1000 Genomes allele frequencies, dbSNP132
rsIDs and earliest appearance in dbSNP. Functional annotation
was added using Ensembl Variant Effect Predictor v2.2 against
Ensembl 64, and included coding consequence predictions,
Sorting Tolerant From Intolerant (SIFT), PolyPhen and Condel
annotations, and Genomic Evolutionary Rate Proﬁling (GERP)
and Grantham Matrix scores. Variants previously reported by
the 1000 Genomes project with minor allele frequency higher
than 0.01 were ﬁltered out. Variants that passed the initial ﬁlter-
ing were compared against 195 non-FH control whole exomes,
processed using the same pipeline, and only FH unique changes
were further assessed. Pathogenicity of any private (ie, speciﬁc
to the FH cohort) variant was examined using previous knowl-
edge and by bioinformatic mutation-prediction tools, which
included: PolyPhen2, SIFT, Condel, Mutation Taster, PhyloP and
Gratham Score algorithm. Sanger sequencing was used to
conﬁrm presence of any identiﬁed predicted pathogenic variant.
Copy number variants analysis
The copy number variants (CNV) analysis uses a read depth
strategy designed to overcome biases associated with sequence
capture and high-throughput sequencing. This set of tools is
implemented in the package ExomeDepth (freely available at
the Comprehensive R Archive Network.23
RESULTS
Overall, the mean read depth for the whole exome sequence
was 72x, with 78.9% of the exome covered at least 20x; and
55.8% of the targeted sequence was covered 50x or more.
LDLR analysis
The average read depth of LDLR exons varied from 136x for
exon 12, to 4x for exon 18 (ﬁgure 1). Using a 16x coverage
threshold, which would give a 99% probability of observing a
rare allele at least three times, all except exons 1 and 18 showed
adequate coverage. Exons 3 and 4 contain the largest number of
reported FH-causing mutations,24 and both these exons were
well covered (mean depth 92 and 57, respectively).
As shown in table 1, in 14 out of the 48 samples, a
FH-unique variant in the LDLR was called, in 11 of these the
variant has been previously reported to be FH-causing.25
All these variants were conﬁrmed to be correct by Sanger
sequencing of duplicate DNA samples (not shown). The variants
included ﬁve different missense mutations and ﬁve nonsense
mutations. The two novel LDLR variants included: c.695-6_
698del and c.1776_1778del (p.(G592del)). The c.695-6_698del is
predicted to cause a frameshift and a premature stop codon by
altering LDLR splicing (see online supplementary ﬁgure S1). The
deletion of Glycine at residue 592 is predicted to disrupt pack-
aging of the LDL-R propeller blades in the epidermal growth
factor (EGF) domain, which could affect displacement of the
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ligand from the ligand-binding region (see online supplementary
ﬁgure S2). Of these 14 mutations, all should have been detected
by our standard screening protocol described in the Materials and
methods section, except for c.695-6_698del, where the change
was located in the primer sequence used for PCR.
CNV calling identiﬁed one deletion of exons 11 and 12 (c.
1587−?_1845+?del), and two duplications of exons 3–8 (191−?
_1186+?dup), and exons 13–15 (c.1846−?_2311+?dup), as
shown in ﬁgure 2. All CNVs were conﬁrmed by MLPA (see
online supplementary ﬁgure S3).
APOB analysis
The mean read depth of APOB exons was 93. Exons 26 and 29
were covered on average 135x, whereas exon 1 was covered
only once (ﬁgure 1). Two individuals were found to carry the
FH-causing APOB mutation in exon 26, the p.(R3527Q). There
were no nonsense or frameshift mutations observed in the gene
sequence. One novel non-synonymous variant was found in
exon 26 of APOB, the p.(A3426V), which was unique to the
FH cohort. The variant was predicted as ‘Tolerated’, ‘Benign’
and ‘Polymorphism’ by SIFT, PolyPhen and Mutation Taster,
respectively. Four other FH-unique non-synonymous variants
were observed outside of the ligand-binding domain (see online
supplementary table S1). The functional impact of these var-
iants, as predicted by PolyPhen/SIFT/Mutation Taster, was not
consistent, and whether or not these are FH-causing is unclear.
There were no CNVs found within the APOB gene.
PCSK9 analysis
The mean read depth of the PCSK9 exons was 23. Of these,
only 58% of the gene coding sequence had the mean coverage
higher than 16, whereas exons 1, 6, 10, 11 and 12 were covered
4x on average (ﬁgure 1). Exon 7, where the common UK
FH-causing mutation (c.1120G>T, p.(D374Y)) occurs, was
covered 36x. Two novel non-synonymous variants were called
by the exome sequencing, c.1027G>C and c.1028A>C, both
present in the same sample. However, despite the high read
depth (51x and 50x), and the high number of read count for the
novel alleles (19 and 26) (see online supplementary ﬁgure S4)
the Sanger sequencing did not conﬁrm the variants. There were
no CNVs observed in PCSK9.
LDLRAP1 analysis
The average read depth of LDLRAP1was 36 with all, except exons
1 and 9 covered above the 16x threshold (ﬁgure 1). The LDLRAP1
variant analysis was performed using a homozygosity-based strat-
egy, and the presence of compound heterozygote variants was
also assessed. There were no homozygous or compound heterozy-
gous functional changes within the gene in any of the individuals.
One patient was found to be heterozygous for a known Sicilian/
Sardinian ARH mutation, the c.432_433insA, p.(A145KfsX26),
Table 1 Summary of pathogenic single nucleotide changes and small deletions/insertions in the FH genes
Gene Samples (n) Nucleotide change Functional effect Depth Quality Comments
LDLR 1 c.326G>A p.(C109Y) 43 506 known FH mutation
1 c.1690A>C p.(N564H) 36 343 known FH mutation
1 c.1823C>T p.(P608L) 82 1214 known FH mutation
1 c.2054C>T p.(P685L) 20 135 known FH mutation
1 c.2479G>A p.(V827I) 65 749 known FH mutation
2 c.682G>T p.(E228X) 13 155 known FH mutation
1 c.1048C>T p.(R350X) 60 816 known FH mutation
1 c.1150C>T p.(Q384X) 20 275 known FH mutation
1 c.1685G>A p.(W562X) 41 701 known FH mutation
1 c.2140+1G>A Splicing 22 258 known FH mutation
1 c.695-6_698del Splicing 36 1543 novel
2 c.1776_1778del p.(G592del) 148 2634 novel
APOB 1 c.10277G>A p.(A3426V) 192 2785 novel
2 c.10580C>T p.(R3527Q) 161 2144 known FH mutation
PCSK9 1 c.1027G>C p.(D343H) 51 44 false positive
1 c.1028A>C p.(D343A) 50 201 false positive
LDLRAP1 1 c.432_433insA p.(A145KfsX26) 90 2186 heterozygous
‘Depth’ refers to the coverage depth; ‘Quality’ values are Phred-like quality scores generated by SAMtools.
Figure 1 The exonic coverage of FH
genes: APOB, LDLR, LDLRAP1 and
PCSK9 in a standard box plot (the
minimum, lower quartile, median,
upper quartile and maximum for each
gene exon). The horizontal dashed line
indicates the 16x coverage, when the
probability of observing a rare allele at
least 3 times is 99%. The additional
Y-axis describes GC content
(0.4=40%, 0.5=50%, etc) for a given
exon, shown as rhombuses.
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which is a frameshift mutation resulting in a truncated peptide
formation.11 26 Further analysis of this sample showed no other
pathogenic variants in known FH genes, which could contribute
to the phenotype. CNV calling did not detect large rearrange-
ments in the LDLRAP1.
DISCUSSION
Current FH-screening methods
The exome sequencing results exposed sensitivity problems
with the current FH mutation-screening methods used in our
research laboratory. Overall, the standard variant-detection
process already in place (HRM, MLPA and Sanger sequencing)
did not detect 17 LDLR mutations (including 3 CNVs) and 2
APOB mutations. Although the HRM has proved to be efﬁcient
at detecting FH variants,16 its sensitivity decreases in some
gene regions, depending on the nucleotide composition of the
fragment. Re-examining previous results for the samples with a
LDLR or APOB variant called by the NGS, we observed that
most of the variants showed a melting curve shift during the
HRM assay, but Sanger sequencing of the identiﬁed gene region
did not detect any heterozygous changes in the sequence
despite being repeated several times (i.e. only the predicted
wild-type sequence was obtained). After the exome sequencing,
the Sanger sequencing was repeated on a duplicate DNA
sample, and the predicted mutations were conﬁrmed to be
present, validating the exome sequencing and variant calling.
Although Sanger sequencing is considered to be the gold stand-
ard mutation-detection method, a combination of PCR arte-
facts and the human error aspect in the protocol appears to be
the main reason for the false negative calling in the original
screening.
Novel LDLR variants
Two novel variants in LDLR were identiﬁed, a deletion of 10 bp
on boundary of intron 4 and exon 5, which is predicted to
cause a frameshift resulting in a premature stop codon by alter-
ing LDLR splicing, and a three bp deletion which deletes
Glycine at residue 592, which is predicted to disrupt packaging
of the LDL-R propeller blades in the EGF domain. Neither of
these variants are found in dbSNP, the 1000 Genomes or the
NHLBI Exome Sequencing Project, and are highly likely to be
FH-causing, although further work is required to conﬁrm this.
Novel APOB variants
APOB codes for one of the largest human proteins, which is the
major component of the LDL-C responsible for binding to
the LDL receptor.27 The actual binding site for the receptor, the
B-site (residues 3386–3396), has been mapped to a region
encoded by exon 26 of the APOB, which is the longest coding
exon known (7572 bps).28 In addition, the C-terminus encoded
by exon 29 of the gene was proposed to function as a modula-
tor of the receptor binding.28 Therefore, our variant analysis
strategy prioritised novel variants located in exons 26 and 29 of
the gene, as these are more likely to cause the FH phenotype.
In this study, there was only one novel variant identiﬁed in the
exon 26 of APOB, the c.10277G>A (p.(A3426V)), which was
not observed previously by the dbSNP, the 1000 Genomes or
the NHLBI Exome Sequencing Project. The variant was not
present in the 195 non-FH exomes from the UK10K project,
which were processed using the same pipeline, increasing the
likelihood that it is in fact disease-causing. The novel p.
Figure 2 Copy Number Variants (CNVs) in LDLR gene. A:
heterozygous duplication of exons 3–8. B: heterozygous deletion of
exons 11 and 12. C: heterozygous duplication of exons 13–15. All
identiﬁed by ExomeDepth in the exome sequencing data. The
crosses show the ratio of observed/expected number of reads for
the test sample. The grey shaded region shows the estimated 99%
CI for this observed ratio in the absence of CNV call. The presence
of contiguous exons with read count ratio located outside of the CI
is indicative of a heterozygous deletion or duplication in a sample.
Exons 1 and 18 were excluded from the analysis (not shown on the
graph) as they did not reach the threshold of 100 for the total
number of reads. All CNVs were conﬁrmed by MLPA experiment
(see online supplementary ﬁgure S3).
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(A3426V) variant is located near to the LDL receptor-binding
site (B-site), and close to the known FH mutation p.(R3527Q),
and although it does not alter the charge at the site, it may
produce a conformational change affecting the LDL-R/ApoB
interaction. This requires further experiments since the current
in silico prediction tools are not able to assess protein–protein
interactions. We will also examine whether or not the variant
cosegregates with the disease. Four other novel APOB variants
were identiﬁed in this group of patients in the N-terminal part
of the protein. Although these variants are less likely to inﬂu-
ence LDL clearance from the blood, since the N-terminal region
of the protein is not involved in interacting with the LDL-R,
some of the variants are predicted as damaging by Polyphen or
SIFT. The aim of this study was to assess the clinical utility of
exome sequencing as a sensitive mutation detection tool, rather
than ﬁnding novel FH mutations. Future work includes the
assessment of novel identiﬁed variants, which will involve
family cosegregation and functional assays.
Promoter region analyses
Most of the sequencing data generated for Mendelian disorders
are focused on the exome, which constitutes around 1% of the
whole human genome. Prediction tools for the analysis of non-
synonymous changes are well established and widely used to
estimate the deleteriousness of amino acid changes. However,
since the majority of human variations are located in the non-
coding regions,29 concern about the bias towards variants in
the protein-coding sequence was highlighted.30 Proving the
pathogenic effect of promoter variants requires use of func-
tional assays. To date, there are 13 LDLR promoter variants pre-
dicted to be causal (in revision10). Disappointingly, but not
surprisingly, given they were not targeted, the exome sequen-
cing data generated by the SureSelect Human All Exon
(Agilent) assay, had negligible coverage of the gene promoter
regions, which can lead to false negative conclusions. Further
updates of the human exome capture assay should include
coverage of the LDLR promoter sequences, which can cause
autosomal dominant disease by altering gene regulation.
Exome sequencing
The SureSelect Human All Exons capture assay is a standard
product, which proved to be efﬁcient at detecting mutations
within the LDLR and the APOB genes. In this sample, 78.9% of
exome bases were covered at least 20 times, which is in line
with the product description ∼80%. For both LDLR and APOB,
the majority of the coding sequence was covered more than the
16x threshold to achieve an estimated 99% chance of seeing a
real variant (present in a heterozygous state) of at least 3
times, and overall 19 mutations, were found by high-
throughput DNA sequencing, which had been missed by con-
ventional methods in our research laboratory. This indicates
increased sensitivity for NGS, which can be due both to the
method used and to the reduced human intervention, and the
highly automated protocol. However, as with many PCR-based
methods, exome sequencing has some limitations when it
comes to ampliﬁcation of highly repetitive regions or sequences
rich in GC content. A highly signiﬁcant negative correlation
between the G/C content and the exome depth was observed
in the FH genes (p=4.9×10−14), as shown in the online supple-
mentary ﬁgure S5. Speciﬁcally, only 58% of the PCSK9 gene
was covered more than 16x, producing unreliable results for
variant calling in a signiﬁcant proportion of the gene’s coding
region. As a result, the two novel non-synonymous PCSK9 var-
iants called by the exome sequencing were not conﬁrmed by
the capillary sequencing, suggesting a high rate of false positive
calls when the coverage is poor. If a read depth threshold of
30x was considered to be required for complete certainty of
variant calling, at which the sensitivity to detect heterozygous
variants was shown to be 100%,31 exons that would be insufﬁ-
ciently covered would also include exons 1, 14 and 18 of LDLR,
exons 2 and 5 of PCSK9, and exons 2, 3 and 7 of LDLRAP1.
Thus, although the quality of the produced data is good, valid-
ation of called variants in poorly covered regions is still neces-
sary. Applying more stringent ﬁlters to the raw data increases
the speciﬁcity of the calling. However, it may also lead to false
negative results, since not all of the exome’s regions are equally
covered. Newer versions of the SureSelect assay show markedly
improved coverage of exons that were previously poorly covered
(unpublished data), so we can expect the sensitivity of exome
sequencing to improve.
The Agilent SureSelect assay was efﬁcient in capturing the
exon–intron junctions, covering on average 80–100bps of the
intronic regions. This was an advantage over our current screen-
ing protocol, and enabled us to detect a novel variant, the
c.695-6_698del, which is partially positioned on the annealing
site for the sequencing primer routinely used in our lab.
The methodology behind the ExomeDepth package23 proved
to be robust, and enabled us to use the exome data, which are
composed of short sequence reads for exonic regions, to detect
large gene rearrangements, which are known in the LDLR to be
usually due to intronic Alu sequence misparing.32 33 The
method was shown to allow identiﬁcation of heterozygous
CNVs within the LDLR gene, which were missed by the cur-
rently used MLPA. However, in order to maximise the sensitiv-
ity and to minimise the noise created by technical variability
between samples, CNV analysis by Exome Depth requires
quality data of well-matched exomes (>6 samples), that is,
sequenced under the exact same conditions.
The greater time efﬁciency of the exome sequencing is a signiﬁ-
cant advantage over the current screening methods. Although
each called variant currently needs to be individually conﬁrmed
by Sanger sequencing before a mutation report can be prepared,
analysing a number of patients in parallel in a short period of
time is likely to be an efﬁcient way forward for screening of het-
erogeneous FH patients. More importantly, limited use of manual
checks and human intervention reduce the issues of possible
human error. The cost efﬁciency of NGS is also increasing. The
development of novel approaches of gene-targeted sequencing,
using Illumina MiSeq platform, reduces not only the costs of
sequencing itself but also the time spent on data analysis and
computer storage requirements. The possibility of designing
custom amplicons for each disease, recently offered by Illumina
TruSeq Custom Amplicon or Agilent HaloPlex products, will also
improve the capture of promoters and other regulatory regions,
which could be omitted in whole exome eequencing.
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